Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
复制标题
DOI：
10.1371/journal.pone.0160576
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Hanafusa T
中科院分区：
文献类型：
--
作者：
Haseda F;Imagawa A;Nishikawa H;Mitsui S;Tsutsumi C;Fujisawa R;Sano H;Murase-Mishiba Y;Terasaki J;Sakaguchi S;Hanafusa T
暴发性1型糖尿病（FT1D）是1型糖尿病的一种独特亚型，如果不及时诊断和治疗是致命的。目前，尚无可用于FT1D早期和预测性检测的生物标志物。首先，我们对3例FT1D患者的6份血清样本（每例患者急性期1份，亚急性期1份）进行血清分析。其次，采用ELISA法检测30例FT1D患者（急性期和亚急性期）、13例FT1D慢性期患者、32例自身免疫性1型（1A型）糖尿病（T1AD）、30例2型糖尿病（T2D）、23例自身免疫性甲状腺疾病（AITD）患者和31例健康对照（HC）患者血清中的抗体滴度。血清分析显示，3例FT1D患者均在急性期出现9种高信号抗体。其中，FT1D患者急性期抗cd300e抗体滴度明显高于T1AD、T2D、AITD和HC患者（P<0.01）。FT1D急性期抗cd300e抗体滴度也高于亚急性期（P = 0.0018， Wilcoxon sign -rank检验）。FT1D患者急性期与亚急性期、T1AD、T2D、AITD、HC患者抗lgals3抗体滴度无差异。FT1D患者血清中抗cd300e抗体滴度较高。该抗体可能是一种诊断标志物，为FT1D的发病机制提供新的认识。
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D. First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC). Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC. The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.